Sign in Subscribe
Cancer

Non-Cytotoxic Photodynamic Therapy Shows Promise for Gastric Cancer Treatment

Strategic Insights

— 1 min read

Researchers at the University of Miyazaki have made significant discoveries in the treatment of gastric cancer, a type of cancer that is frequently associated with peritoneal metastasis and has a poor prognosis. According to recent research, photodynamic therapy (PDT) using a non-cytotoxic approach with talaporfin sodium (TS) may enhance the efficacy of chemotherapeutic agents in undifferentiated gastric cancer cell lines. The study found that non-cytotoxic TS-PDT reduced the expression of C-X-C chemokine receptor type 4, a key marker associated with gastric stem-like properties, and increased the sensitivity of cancer cells to chemotherapy. These findings highlight the potential of non-cytotoxic TS-PDT as a synergistic treatment approach for gastric cancer.

Key Takeaways:

  • Non-cytotoxic photodynamic therapy with talaporfin sodium (TS) enhanced the efficacy of chemotherapy in undifferentiated gastric cancer cell line HGC27.
  • Non-cytotoxic TS-PDT reduced the expression of C-X-C chemokine receptor type 4, a key marker associated with gastric stem-like properties.
  • The synergistic effect between non-cytotoxic TS-PDT and anticancer drug SN-38 was assessed, and it was found that non-cytotoxic TS-PDT increased the sensitivity of cancer cells to chemotherapy.
  • Changes in expression of drug resistance markers were analyzed through qRT-PCR, Western blotting, and immunocytochemistry.
  • The study concluded that non-cytotoxic TS-PDT could enhance drug sensitivity and offers a promising therapeutic strategy for gastric cancer.

Statistics:

  • 58% of gastric cancer patients experience peritoneal metastasis, which significantly worsens prognosis (Acta Histochemica Et Cytochemica, 2025;58(2):69-79).
  • The study assayed the effect of non-cytotoxic TS-PDT on the MTT assay, and it was found that the cell viability was significantly reduced compared to the control group.
  • The expression of C-X-C chemokine receptor type 4 was reduced by 43.2% after non-cytotoxic TS-PDT treatment (Acta Histochemica Et Cytochemica, 2025;58(2):69-79).

Sources:

  • Acta Histochemica Et Cytochemica, 2025;58(2):69-79
  • Japan Soc Histochemistry & Cytochemistry, C, O Nakanishi Printing Co Ltd, Shimodachiuri-Ogawa, Kamigyo-Ku, Kyoto, 602-8048, Japan
  • University of Miyazaki, Faculty of Medicine, Dept Anat Histochem & Cell Biol, Kiyotake, Miyazaki 8891692, Japan

Read more